Los Angeles Capital Management
CADL icon

Los Angeles Capital Management’s Candel Therapeutics CADL Stock Holding History

Los Angeles Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,810
Closed -$126K – 1379
2025
Q2 		$126K Buy
+24,810
New +$128K ﹤0.01% 1238

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Los Angeles Capital Management's CADL Position: Q3 2025 in Review

Los Angeles Capital Management sold out of Candel Therapeutics (CADL) in Q3 2025, closing a stake of 24,810 shares — an estimated $126K sold.

Los Angeles Capital Management first reported a position in CADL in Q2 2025 and held it in 1 quarter. The position peaked at $126K in Q2 2025. 81 funds tracked by Wall St. Rank hold CADL as of Q3 2025.

  • Los Angeles Capital Management reported no remaining Candel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 24,810 Candel Therapeutics shares in Q3 2025, an estimated $126K.
  • Los Angeles Capital Management first reported a position in Candel Therapeutics in Q2 2025 and held it in 1 quarter.
  • Los Angeles Capital Management's Candel Therapeutics position peaked at $126K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2025.

Based on Los Angeles Capital Management's 13F filing for Q3 2025, filed 20 Oct 2025.